Sign in
Taking people in South KoreaPhase 1

Tests SNE-101 safety in people with acute ischemic stroke

Tests SNE-101 for safety and tolerability in adults with acute ischemic stroke.

Key facts

Who runs it
S&Ebio Co. Ltd.
Where
Seoul and Suwon, South KoreaSee the 3 sites
Trial code
Registry title
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
Status
Recruiting
Phase
Phase 1
People taking part
18 people, planned
Started
22 Jun 2026
Expected to end
31 Mar 2027
Type of study
Interventional
Treatments tested
  • SNE-101
Record updated
6 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had an acute ischemic stroke in the middle cerebral artery area, with moderate to severe symptoms and new weakness. It tests the safety of SNE-101.

Age
19 years or older
Sex
Women and men can both join.
Disease stage
Acute ischemic stroke within 5 days of symptom onset. On DWI scan, the stroke is in the middle cerebral artery area and at least 20 mm in its longest diameter. NIHSS score is between 5-21, with new weakness and no impaired consciousness.
Earlier treatment
People who had no clot-dissolving treatment or procedure to reopen the artery can join. People who had one but show no recovery after 2 days of observation can also join.

Main reasons for not taking part

  • Disability before the stroke (pre-stroke mRS ≥ 2)
  • Likely to recover on its own
  • Severe heart, liver, kidney or infectious disease, or cancer, within the past 5 years
  • Severe psychiatric illness or dementia before the stroke
  • Cannot have an MRI, is pregnant or breastfeeding, or joined another trial in the past 3 months

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Adults with 19 years or older
  • Patients within 5 days of symptom onset who have not received thrombolytic therapy or undergone endovascular reperfusion procedures
  • Patients within 5 days of symptom onset who have received thrombolytic therapy or undergone endovascular reperfusion procedures but show no clinical recovery after 2 days of observation
  • Imaging findings must meet both of the following:; Infarction within the middle cerebral artery territory on diffusion-weighted imaging (DWI); Infarct size ≥ 20 mm in the longest diameter on DWI
  • Neurological status meeting all three of the following NIHSS criteria:; Moderate to severe neurological deficit (NIHSS score between 5-21); New onset of motor weakness (score 2-4 in at least one of NIHSS items 5a, 5b, 6a, or 6b); No impaired consciousness (score 0-1 on NIHSS items 1a, 1b, and 1c)
  • Voluntary written informed consent

Who cannot take part

  • Pre-stroke disability (pre-stroke mRS ≥ 2)
  • Likely to recover spontaneously, based on all three of:; No longer meeting the NIHSS inclusion criteria 48 hours post-thrombolysis or endovascular therapy; Lacunar stroke due to small vessel occlusion; SAFE (Shoulder Abduction and Finger Extension) score ≥ 5
  • Presence or risk of malignant middle cerebral artery infarction with brain edema
  • Significant medical history within the past 5 years:; Severe heart failure; Severe infectious disease; Severe hepatic failure or renal failure; Newly diagnosed or actively treated cancer; Any systemic disease deemed by investigator to significantly reduce life expectancy; Any condition likely to hinder follow-up during the study
  • Diagnosed severe psychiatric illness:; Moderate or greater depression pre-stroke with functional impairment and suicide risk; Pre-stroke dementia interfering with daily living (CDR ≥ 2)
  • Subjects are ineligible if they meet any of the following:
  • Contraindication to MRI (e.g., pacemaker)
  • Pregnant or breastfeeding, or unwilling to use effective contraception method for 90 days after last dose
  • Participation in another clinical trial within the past 3 months
  • Any other reason determined by the investigator that would prevent participation

Where in South Korea

  • Ewha Womans University Seoul HospitalSeoul, South KoreaContact: Tae-Jin Song, MD (sub-investigator)Taking people
  • Samsung Medical CenterSeoul, South KoreaContact: Woo-Keun Seo, MD (sub-investigator)Taking people
  • Ajou University HospitalSuwon, South KoreaContact: Jin soo Lee, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke

The group in the trial

  • SNE-101Treatment being tested

    Patients will be given SNE-101, an extracellular vesicle derived from Wharton's jelly mesenchymal stem cells. • Drug: SNE-101 * Three multiple doses of SNE-101 will be administered to three study cohorts , each consisting of 3 to 6 subjects. * SNE-101 will be administered intravenously once a day for 5 days.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label, Single-Arm, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Tolerability of SNE-101 in Patients With Acute Ischemic Stroke
Plain-language title
Tests SNE-101 safety in people with acute ischemic strokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 July 2026